Sirnaomics Ltd. became the first RNA therapeutics company to list on the Hong Kong Stock Exchange (HKEX) with a $64 million initial public offering. Its shares (HKEX:2277) have since surged, rising to HK$93.90 ($12.04) on Jan. 4 following their debut at HK$65.90 per share. Read More

Sihuan Pharmaceutical Holdings Group Ltd.’s subsidiary Xuanzhu Biopharmaceutical Co. Ltd. has raised ¥610.5 million ($96 million) in a series B round led by Sunshine Life Insurance Corp. Ltd. Read More

PERTH, Australia – Australia should be at the front of the line among developed nations when it comes to innovative drugs and devices, but health policies must evolve to respond to changes in technology and global trends, Johnson & Johnson (J&J) said. Although Australia’s health policy has served the country well, tensions in the system are becoming seismic shifts that mirror international trends, J&J said in a recent report on Australia’s health system. Read More

It is acknowledged that the huge bias toward individuals of European ancestry means studies of the contribution of genetics to disease may not translate well to other ethnicities. That point is underlined in the first large-scale investigation of the population structure and demographic history of British Pakistanis, which shows an increased number and length of regions of homozygosity inherited from a common ancestor, and greatly elevated identity by descent, compared to the population at large. Read More

India’s Department of Pharmaceuticals (DOD) released draft guidelines to boost research and development in its pharmaceutical and medical device industries. The document touched on the reasons for a dedicated R&D and innovation policy, which involved reducing import dependence, increasing the speed of biologic and biosimilar development cycles, and tackling infrastructural challenges. Read More

One of the most striking recent changes in the dissemination of biomedical science has been the rapid rise of the preprint. Read More

New hires and promotions in the biopharma industry in Asia-Pacific, including: Biosion, Opthea. Read More

Clinical updates from Asia, including trial initiations, enrollment status and data readouts and publications: Akeso, Antengene, Astrazeneca, Bharat Biotech, Bio-Thera Solutions, Daiichi Sankyo, Dawnrays, Kiniksa, Kintor, Luye, Novavax, Nykode, Ocugen, Pharmabcine, Pluristem, Revive, Ribomic. Read More

Biopharmas in Asia-Pacific raising money in public or private financings: Biondvax, Genfleet. Read More

Biopharma happenings in Asia-Pacific, such as deals and partnerships, grants, preclinical data and other news in brief: Aditxt, Aipharma, Beximco, Immuneoncia, Moderna, Oramed, Oravax Medical, Pfizer, Tan Thanh Holdings Investment Joint Stock, Vir, Wuxi Biologics. Read More

Regulatory snapshots, including drug submissions and approvals, clinical trial approvals and other regulatory decisions and designations in Asia-Pacific: Amniotics, Astrazeneca, Cstone, Daiichi Sankyo, Mesoblast, Novavax, Nrx, RDIF, Regor. Read More